Back Stocks profile

Stock analysis tool for investors

Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE:532488

₹3482.40 -6.40 (-0.18%) 1D

Pharmaceuticals & Biotechnology

Open an Account with Bigul in 5 minutes

Performance

Today’s low

3474.00

Today’s High

3519.00

52W low

2730.00

52W High

4074.40

Open Price

3491.00

Prev. Close

3488.8000

Volume

358034.00

Value

1246817601.60

Fundamentals

Market Cap Cr

92446.80

Price to Earnings

66.80

Price to Book Value

7.20

Dividend Yield

0.90

PE to Growth

-1.60

Op Revenue TTM Cr

7492.77

Net Profit TTM Cr

1382.97

Cash From Operating Activity Cr

2459.73

Return on Equity %

14.28

EMA & SMA

Bullish Moving Averages

0

Bearish Moving Averages

16

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

01 Mar, 2024

58.9

Week

64.5

Month

53

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

3491.80

PIVOT

First Resistance

3509.60

Second Resistance

3536.80

Third Resistance

3554.60

First Support

3464.60

Second Support

3446.80

Third Support

3419.60

Relative Strength Index

29.07

Money Flow Index

32.51

MACD

-56.27

MACD Signal

-35.94

Average True Range

77.73

Average Directional Index

21.51

Rate of Change (21)

-4.73

Rate of Change (125)

-3.05

Commodity Channel Index

-163.7

Williams %R

-95.3

BETA

1 Month

0.3

3 Month

0.63

1 Year

0.51

3 Year

0.11

PRICE CHANGE ANALYSIS

-4.54%

1 Week

Low

High

3465

3655

-4.73%

1 Month

Low

High

3465

3832.8

-8.18%

3 Months

Low

High

3465

4074.4

-2.98%

6 Months

Low

High

3295.3

4074.4

22.39%

1 Year

Low

High

2730

4074.4

Bigul
16 Feb 2024

DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

We herewith enclose the Transcript of earnings conference call held on February 10, 2024.
Bigul
12 Feb 2024

Q3FY24 Quarterly & 9MFY24 Result Announced for Divi's Laboratories Ltd.

Pharmaceuticals company Divi's Laboratories announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: Total Income: Rs 1,950 crore, compared to Rs 1,821 crore in the corresponding quarter of the previous year. Material Consumption: Approximately 39% of sales revenue. Profit Before Tax (PBT): Rs 489 crore, compared to Rs 435 crore in the corresponding quarter of the previous year. Profit After Tax (PAT): Rs 358 crore, compared to Rs 306 crore in the corresponding quarter of the previous year. Standalone Q3FY24: Total Income: Recorded at Rs 1,902 crore in Q3FY24 compared to Rs 1,807 crore in Q3FY23. Profit Before Tax (PBT): Stood at Rs 490 crore in Q3FY24, up from Rs 439 crore in Q3FY23. Profit After Tax (PAT): Amounted to Rs 358 crore in Q3FY24, higher than the Rs 310 crore in Q3FY23. Forex Gain: Registered at Rs 17 crore in Q3FY24, decreased from Rs 49 crore in Q3FY23. Consolidated 9MFY24: Total Income: Rs 5,804 crore, compared to Rs 6,099 crore in the corresponding previous period. Profit After Tax (PAT): Rs 1,062 crore, compared to Rs 1,502 crore in the corresponding previous period. Forex Gain: Rs 32 crore, compared to Rs 134 crore in the previous 9-month period. Standalone 9MFY24: Total Income: For 9MFY24, it amounted to Rs 5,665 crore, down from Rs 6,003 crore in 9MFY23. Profit Before Tax (PBT): For 9MFY24, it was Rs 1,432 crore, a decrease from Rs 1,886 crore in 9MFY23. Profit After Tax (PAT): For 9MFY24, it reached Rs 1,045 crore, down from Rs 1,489 crore in 9MFY23. Forex Gain: For 9MFY24, it stood at Rs 29 crore, a decline from Rs 137 crore in 9MFY23. Result PDF
Bigul
10 Feb 2024

DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

We hereby inform that the audio recording of the earnings call for Q3FY24 held on February 10, 2024 has been updated on the Company''s website.
Bigul
02 Feb 2024

DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of earnings conference call for the quarter and nine months ended December 31, 2023 to be held on February 10, 2024 at 14:00 hrs (IST).
Bigul
30 Jan 2024

DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023

DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2023
Bigul
09 Jan 2024

DIVI'S LABORATORIES LTD. - 532488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended December 31, 2023.
See all News

FAQs

The latest market price of Divi's Laboratories Ltd. on NSE was Rs. 3482.40 as of today.

The opening share price of Divi's Laboratories Ltd. was Rs. 3491.00 as of today.

The 52-week high share price of Divi's Laboratories Ltd. was Rs. 4074.40.

The 52 week low share price of Divi's Laboratories Ltd. was Rs. 2730.00.

Divi's Laboratories Ltd. has a market cap of Rs. 92446.80 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Divi's Laboratories Ltd. is -1.60. Please refer to the Fundamentals section for further details.

The operating revenue for Divi's Laboratories Ltd. in the last FY was Rs.  7492.77 crore. Please refer to the Financials section for further details.

The Net Profit for Divi's Laboratories Ltd. in the last FY was Rs. 1382.97 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Divi's Laboratories Ltd. was on 2023-08-11 for Rs. 30 per share. According to today’s share price, the dividend yield of Divi's Laboratories Ltd. stands at 0.90. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Divi's Laboratories Ltd. was as of 2015-09-23. The bonus ratio declared in this issue was 1:1. Please refer to the Corporate Actions section for further details.

The latest split issue declared by Divi's Laboratories Ltd. was as of 2007-08-03. The split ratio declared in this issue was 10:2. Please refer to the Corporate Actions section for further details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Divi's Laboratories Ltd..